These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 23317279)
1. Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Guo CL; Yang HC; Yang XH; Cheng W; Dong TX; Zhu WJ; Xu Z; Zhao L Asian Pac J Cancer Prev; 2012; 13(11):5909-13. PubMed ID: 23317279 [TBL] [Abstract][Full Text] [Related]
2. Increased frequency of Foxp3+ regulatory T cells in mice with hepatocellular carcinoma. Du Y; Chen X; Huang ZM; Ye XH; Niu Q Asian Pac J Cancer Prev; 2012; 13(8):3815-9. PubMed ID: 23098476 [TBL] [Abstract][Full Text] [Related]
3. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells. Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540 [TBL] [Abstract][Full Text] [Related]
4. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208 [TBL] [Abstract][Full Text] [Related]
5. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Unitt E; Rushbrook SM; Marshall A; Davies S; Gibbs P; Morris LS; Coleman N; Alexander GJ Hepatology; 2005 Apr; 41(4):722-30. PubMed ID: 15791620 [TBL] [Abstract][Full Text] [Related]
6. Increased liver-infiltrating CD8+FoxP3+ regulatory T cells are associated with tumor stage in hepatocellular carcinoma patients. Yang ZQ; Yang ZY; Zhang LD; Ping-Bie ; Wang SG; Ma KS; Li XW; Dong JH Hum Immunol; 2010 Dec; 71(12):1180-6. PubMed ID: 20870003 [TBL] [Abstract][Full Text] [Related]
7. Phenotypic analysis of tumor-infiltrating lymphocytes in hepatocellular carcinoma. Chen CH; Lee HS; Huang GT; Yang PM; Yu WY; Cheng KC; Lee PH; Jeng YM; Chen DS; Sheu JC Hepatogastroenterology; 2007; 54(77):1529-33. PubMed ID: 17708291 [TBL] [Abstract][Full Text] [Related]
8. Increased CD4(+) CD69(+) CD25(-) T cells in patients with hepatocellular carcinoma are associated with tumor progression. Zhu J; Feng A; Sun J; Jiang Z; Zhang G; Wang K; Hu S; Qu X J Gastroenterol Hepatol; 2011 Oct; 26(10):1519-26. PubMed ID: 21557772 [TBL] [Abstract][Full Text] [Related]
9. Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Huang Y; Wang FM; Wang T; Wang YJ; Zhu ZY; Gao YT; Du Z Digestion; 2012; 86(4):329-37. PubMed ID: 23207161 [TBL] [Abstract][Full Text] [Related]
11. [Significance of the expression of lymphocytes and cytokines infiltrating in HCC]. Ye YB; Peng F; Li JY; Lin LP; Zheng XW; Zhou D; Li C; Li QL; Cai XW Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Oct; 27(10):1056-60. PubMed ID: 21968301 [TBL] [Abstract][Full Text] [Related]
12. Expression of Fas/FasL in CD8+ T and CD3+ Foxp3+ Treg cells--relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients. Guo CL; Yang XH; Cheng W; Xu Y; Li JB; Sun YX; Bi YM; Zhang L; Wang QC Asian Pac J Cancer Prev; 2014; 15(6):2613-8. PubMed ID: 24761872 [TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management. Shirabe K; Motomura T; Muto J; Toshima T; Matono R; Mano Y; Takeishi K; Ijichi H; Harada N; Uchiyama H; Yoshizumi T; Taketomi A; Maehara Y Int J Clin Oncol; 2010 Dec; 15(6):552-8. PubMed ID: 20963618 [TBL] [Abstract][Full Text] [Related]
14. Increased frequency of CD4+CD25(high)FoxP3+ regulatory T cells in patients with hepatocellular carcinoma. Feng X; Li B; Ye H; Long D Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):309-14. PubMed ID: 21633918 [TBL] [Abstract][Full Text] [Related]
15. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma. Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363 [TBL] [Abstract][Full Text] [Related]
16. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. Rohr-Udilova N; Klinglmüller F; Schulte-Hermann R; Stift J; Herac M; Salzmann M; Finotello F; Timelthaler G; Oberhuber G; Pinter M; Reiberger T; Jensen-Jarolim E; Eferl R; Trauner M Sci Rep; 2018 Apr; 8(1):6220. PubMed ID: 29670256 [TBL] [Abstract][Full Text] [Related]
17. Global microarray profiling identified Weng Q; Chen M; Li M; Zheng YF; Shao G; Fan W; Xu XM; Ji J J Med Genet; 2019 Jan; 56(1):32-38. PubMed ID: 30120213 [TBL] [Abstract][Full Text] [Related]
18. Amphiregulin activates regulatory T lymphocytes and suppresses CD8+ T cell-mediated anti-tumor response in hepatocellular carcinoma cells. Yuan CH; Sun XM; Zhu CL; Liu SP; Wu L; Chen H; Feng MH; Wu K; Wang FB Oncotarget; 2015 Oct; 6(31):32138-53. PubMed ID: 26451607 [TBL] [Abstract][Full Text] [Related]
19. Naive Treg-like CCR7(+) mononuclear cells indicate unfavorable prognosis in hepatocellular carcinoma. Shi JY; Duan M; Sun QM; Yang L; Wang ZC; Mynbaev OA; He YF; Wang LY; Zhou J; Tang QQ; Cao Y; Fan J; Wang XY; Gao Q Tumour Biol; 2016 Jul; 37(7):9909-17. PubMed ID: 26813566 [TBL] [Abstract][Full Text] [Related]
20. Regulatory T cells, especially ICOS Tu JF; Ding YH; Ying XH; Wu FZ; Zhou XM; Zhang DK; Zou H; Ji JS Sci Rep; 2016 Oct; 6():35056. PubMed ID: 27725696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]